SR

Sartorius AGFRA Sartorius Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

16.105

Large

Exchange

XFRA - Deutsche Boerse AG

SRT.F Stock Analysis

SR

Avoid

Based on Eyestock quantitative analysis, SRT.F`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

27/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-52.2 %

Greatly overvalued

Market cap $B

16.105

Dividend yield

0.27 %

Shares outstanding

68.416 B

Sartorius AG is a DE-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Goettingen, Niedersachsen and currently employs 15,942 full-time employees. Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. The company operates through two segments: Bioprocess Solutions and Lab Products and Services. The Bioprocess Solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, and filter technology for clarification, among others. The Lab Products and Services segment provides instruments, consumables and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation and membrane filter systems for sterility testing of parenterals.

View Section: Eyestock Rating